AAKHA BIOLOGICS INC.

FRISCO, TX · Founded 2022 · CIK 0002030720 · Biotech · Private

Biotech therapeutics for rare and orphan diseases

aakha.bio →
Grants
$400K
1 award
Sector median: 1
Raised
$750K
1 Form D · Jul 2024
27 months since last filing
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · A novel MICA/B based tumor-centric bispecific antibody that enhances NK cell activity in a hostile tumor microenvironment$400,000
Private capital raisedForm D · SEC$750,000
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2584PRAETEGO, INC.—$783K
2585Indigo Biosciences Inc.—$782K
2586Bit Discovery, Inc.—$760K
2587AAKHA BIOLOGICS INC.—$750K
2588ENDURE BIOTHERAPEUTICS, INC.——
2589ZIPPIN BIO CORPORATION——
2590SIRPANT IMMUNOTHERAPEUTICS INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • Errik AndersonDirector
  • Hemanta BaruahDirector · Executive Officer
  • George Mabry IIIDirector
  • Christopher PachecoDirector

Patents

USPTO · 0 granted of 3
  • Mhc Class I Chain-related Protein A (mica)-specific Antibodies And Uses Thereofapplication
  • Mhc Class I Chain-related Protein A (mica)-specific Antibodies And Uses Thereofapplication
  • Mhc Class I Chain-related Protein A (mica)-specific Antibodies And Uses Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.